Francesc Olivares

ORCID: 0009-0005-9362-3120
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Tuberculosis Research and Epidemiology
  • Immune Cell Function and Interaction
  • Cancer Research and Treatments
  • Bladder and Urothelial Cancer Treatments
  • Cancer Cells and Metastasis
  • Infectious Diseases and Mycology
  • Mycobacterium research and diagnosis
  • Gut microbiota and health

Hospital Del Mar
2023-2024

Universitat Autònoma de Barcelona
2011-2013

In low-income countries some infections caused by nontuberculous mycobacteria are misdiagnosed as multidrug-resistant tuberculosis. most of these settings the observation microscopic cords is only technique used to identify Mycobacterium tuberculosis in laboratory. this article we definitively demonstrate that abscessus, an emerging pulmonary pathogen, also forms cords.

10.1128/jcm.02322-10 article EN Journal of Clinical Microbiology 2011-04-14

Mycobacterium bovis bacillus Calmette-Guérin is the most effective treatment for high risk noninvasive bladder cancer. Although immunotherapy clearly decreases recurrence and progression rates, side effects are common infection with has been described. For these reasons it necessary to find safer alternatives live bacillus. We explored possibility of using killed but metabolically active Calmette-Guérin.T24, J82 RT4 tumor cell lines were cultured irradiation or heat treated Connaught....

10.1016/j.juro.2013.12.002 article EN The Journal of Urology 2013-12-10

The aim of this study was to determine whether low HLA-I expression and NK cells infiltration are related prognostic features in breast cancer, as observed cancers other locations non-hormone dependent cancers. Particularly, we explored their relation infiltrated axillary lymph nodes (ALNs), with the finding new predictors helping decide extent surgery.

10.2147/bctt.s476721 article EN cc-by-nc Breast Cancer Targets and Therapy 2024-10-01
Coming Soon ...